Erasca, Inc. (ERAS)
3.28
+0.09
(+2.82%)
USD |
NASDAQ |
Dec 05, 14:58
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 930.57M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 1.92% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 2.675 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.1388 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
Profile
| Erasca, Inc. is a clinical stage precision oncology company. It focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. It has assembled a wholly owned or controlled RAS/MAPK pathway focused pipeline comprising modality-agnostic programs. The company was founded by Jonathan E. Lim and Kevan Shokat on July 2, 2018 and is headquartered in San Diego, CA. |
| URL | http://www.erasca.com |
| Investor Relations URL | https://investors.erasca.com/ |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Mar. 19, 2026 (est.) |
| Last Earnings Release | Nov. 12, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Erasca, Inc. is a clinical stage precision oncology company. It focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. It has assembled a wholly owned or controlled RAS/MAPK pathway focused pipeline comprising modality-agnostic programs. The company was founded by Jonathan E. Lim and Kevan Shokat on July 2, 2018 and is headquartered in San Diego, CA. |
| URL | http://www.erasca.com |
| Investor Relations URL | https://investors.erasca.com/ |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Mar. 19, 2026 (est.) |
| Last Earnings Release | Nov. 12, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |